Short acting GLP-1 receptor agonist (injectable)
Exenatide 10 ug subcutaneous twice daily
EXEN_SC_10UG_BID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.56 (-0.87 to -0.25) | 0.24 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.83 (-1.04 to -0.62) | 0.44 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.56 (0.01 to 1.12) | 0.15 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.56 (-0.99 to -0.02) | 0.17 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.90 (-1.58 to 0.57) | 0.29 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Standard care or no added treatment | MD -0.10 (-1.07 to 0.77) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.67 (-1.19 to 0.09) | 0.38 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.74 (-1.46 to 0.10) | 0.87 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.77 (-2.85 to -0.69) | 0.53 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.65 (-2.41 to -0.90) | 0.72 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.19 (-5.17 to 3.30) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.12 (-5.98 to 3.21) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.55 (-3.88 to 0.95) | 0.93 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.46 (1.13 to 5.51) | 0.29 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.15 (0.02 to 0.68) | 0.68 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 6.05 (1.89 to 18.11) | 0.21 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.84 (1.24 to 2.68) | 0.38 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.25 (0.49 to 3.02) | 0.41 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.78 (-4.28 to -1.32) | 0.60 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.17 (-2.08 to 8.42) | 0.51 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.96 (0.75 to 1.21) | 0.50 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.30 (1.28 to 3.98) | 0.37 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.72 (3.04 to 4.59) | 0.36 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.88 (2.22 to 3.80) | 0.48 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.23 (0.99 to 1.53) | 0.63 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.60 (1.11 to 2.30) | 0.52 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 7.47 (1.45 to 49.00) | 0.18 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.30 (0.02 to 2.69) | 0.69 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.60 (0.04 to 8.71) | 0.57 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.31 (0.00 to 16.10) | 0.61 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.13 (-10.82 to 4.73) | 0.22 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.19 (0.00 to 6.88) | 0.78 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.60 (2.67 to 8.28) | 0.36 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.90 (1.81 to 30.04) | 0.38 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.84 (0.91 to 4.03) | 0.52 |
Trials
- S0030762017 · 35 randomized · 24 weeks
- S0030862017 · 159 randomized · 24 weeks
- NCT02690883Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study2016 · 92 randomized · 24 weeks
- NCT02449603Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study2015 · 104 randomized · 16 weeks
- S0030442015 · 95 randomized · 24 weeks
- S0030302015 · 66 randomized · 52 weeks
- NCT02325960A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in T2DM Patients Inadequately Controlled With Metformin Monotherapy2015 · 45 randomized · 16 weeks
- PREVAILPreserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)2014 · 103 randomized · 8 weeks
- NCT01776788Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on β-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients2012 · 130 randomized · 12 weeks
- NCT01590433A Prospective Study of Patterns, Predictors, and Mechanisms of Weight Loss With Exenatide Treatment in Overweight and Obese Women Without Diabetes2012 · 182 randomized · 52 weeks
- NCT01147627Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial2010 · 416 randomized · 48 weeks
- AWARD-1A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)2010 · 978 randomized · 52 weeks
- S0030792010 · 36 randomized · 5 weeks
- NCT01270191The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients2010 · 40 randomized · 24 weeks
- NCT00877890A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus2009 · 254 randomized · 24 weeks
- NCT00960661A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea2009 · 637 randomized · 30 weeks
- NCT00917267A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications2009 · 681 randomized · 26 weeks
- NCT00766857The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial2009 · 26 weeks
- NCT00943917Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus2009 · 155 randomized · 24 weeks
- NCT00775684A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes2008 · 47 randomized · 26.07 weeks
- NCT00577824Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled2008 · 181 randomized · 24 weeks
- NCT00701935Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin2008 · 80 randomized · 26.07 weeks
- NCT00717457Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus2008 · 1,189 randomized · 52 weeks
- GETGOAL-XA Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2008 · 639 randomized · 24 weeks
- NCT00971659Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily2008 · 48 randomized · 4 weeks
- NCT00603239Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin2008 · 165 randomized · 26 weeks
- NCT00765817A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications2008 · 261 randomized · 30 weeks
- NCT00434954Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment2007 · 494 randomized · 26 weeks
- NCT00518115A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus2007 · 361 randomized · 16 weeks
- NCT00546728The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance2007 · 50 randomized · 13.04 weeks
- NCT00500370A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients2007 · 163 randomized · 24 weeks
- LEAD-6Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes2007 · 464 randomized · 26 weeks
- NCT01432405Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus2007 · 24 randomized · 52.14 weeks
- NCT00516074A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes2007 · 54 randomized · 12 weeks
- NCT00135330An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin2006 · 137 randomized · 20 weeks
- NCT00375492Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program2006 · 194 randomized · 24 weeks
- NCT00382239A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled2006 · 153 randomized · 12 weeks
- NCT00360334An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone2006 · 235 randomized · 26 weeks
- NCT00359762Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)2006 · 1,029 randomized · 234.81 weeks
- NCT00082407Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin2003 · 505 randomized · 52 weeks